New York: Dynavax (NASDAQ:DVAX) Stock Has Just Had Its “Buy” Rating Reiterated by Cantor Fitzgerald. Shares now Have a $27.0000 Target

May 17, 2018 - By Alfred Lee

Dynavax Technologies Corporation (NASDAQ:DVAX) Logo

Investors sentiment decreased to 1 in 2017 Q4. Its down 1.06, from 2.06 in 2017Q3. It dropped, as 15 investors sold Dynavax Technologies Corporation shares while 43 reduced holdings. 31 funds opened positions while 27 raised stakes. 43.53 million shares or 3.88% more from 41.91 million shares in 2017Q3 were reported.

Sg Americas Securities Ltd owns 8,617 shares for 0% of their portfolio. Voya Inv Limited Co reported 27,887 shares. Lazard Asset Limited Liability Com invested in 18,352 shares. First Advisors Limited Partnership invested in 0% or 106,402 shares. Clearbridge Lc owns 552,660 shares or 0.22% of their US portfolio. State Street Corporation holds 0.01% or 4.58M shares in its portfolio. State Common Retirement Fund reported 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Federated Inc Pa invested 0.13% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Vantage Inv Advsrs Limited Liability Company owns 500 shares. Parallax Volatility Advisers Limited Partnership owns 9,366 shares. Trexquant Limited Partnership, Connecticut-based fund reported 27,577 shares. Ameritas Prtnrs invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Wellington Management Group Inc Ltd Liability Partnership owns 54,289 shares or 0% of their US portfolio. Moreover, Victory Management has 0% invested in Dynavax Technologies Corporation (NASDAQ:DVAX). 86,190 are owned by Credit Suisse Ag.

Since December 13, 2017, it had 0 insider purchases, and 5 selling transactions for $1.07 million activity. COFFMAN ROBERT also sold $141,750 worth of Dynavax Technologies Corporation (NASDAQ:DVAX) shares. $57,511 worth of Dynavax Technologies Corporation (NASDAQ:DVAX) was sold by Johnson David Louis.

Dynavax (NASDAQ:DVAX) Rating Reaffirmed

In a report sent to clients and investors this morning, Cantor Fitzgerald restate their “Buy” rating on Dynavax (NASDAQ:DVAX) shares. The PT means a possible upside of 61.68 % from company’s current stock price.

Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage

Among 5 analysts covering Dynavax (NASDAQ:DVAX), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Dynavax has $3000 highest and $2500 lowest target. $26.40’s average target is 58.08% above currents $16.7 stock price. Dynavax had 10 analyst reports since January 22, 2018 according to SRatingsIntel. As per Tuesday, March 27, the company rating was maintained by RBC Capital Markets. The firm earned “Hold” rating on Wednesday, February 14 by J.P. Morgan. As per Monday, April 16, the company rating was maintained by Cantor Fitzgerald. The firm has “Overweight” rating given on Thursday, May 10 by JP Morgan. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Neutral” rating by JP Morgan on Wednesday, February 14. RBC Capital Markets maintained the stock with “Buy” rating in Thursday, March 8 report. The rating was upgraded by RBC Capital Markets to “Buy” on Monday, January 22. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) has “Buy” rating given on Tuesday, May 8 by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald on Thursday, March 8 with “Buy”. The firm has “Buy” rating by Cowen & Co given on Tuesday, April 17.

The stock decreased 13.70% or $2.65 during the last trading session, reaching $16.7. About 5.83 million shares traded or 250.11% up from the average. Dynavax Technologies Corporation (NASDAQ:DVAX) has risen 231.67% since May 18, 2017 and is uptrending. It has outperformed by 220.12% the S&P500.

Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on August, 1. They expect $-0.58 earnings per share, down 41.46 % or $0.17 from last year’s $-0.41 per share. After $-0.63 actual earnings per share reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -7.94 % EPS growth.

Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company has market cap of $1.04 billion. The Company’s product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. It currently has negative earnings. The company's lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies.

More notable recent Dynavax Technologies Corporation (NASDAQ:DVAX) news were published by: Streetinsider.com which released: “Dynavax Technologies (DVAX) option implied volatility, to present new SD-101 in combination with Keytruda data at …” on May 17, 2018, also Nasdaq.com with their article: “Market Trends Toward New Normal in Dynavax Technologies, Synergy Resources, Allscripts Healthcare Solutions …” published on May 16, 2018, Globenewswire.com published: “Dynavax to Host First Quarter 2018 Financial Results Conference Call” on May 02, 2018. More interesting news about Dynavax Technologies Corporation (NASDAQ:DVAX) were released by: Benzinga.com and their article: “JPMorgan Sees Entry Point In Dynavax Ahead Of June Oncology Conference” published on May 10, 2018 as well as Streetinsider.com‘s news article titled: “Dynavax (DVAX) to Present New Data for SD-101 in Combination with KEYTRUDA at ASCO” with publication date: May 16, 2018.

Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.